Pregled bibliografske jedinice broj: 783025
Cyclosporine in chronic idiopathic urticaria
Cyclosporine in chronic idiopathic urticaria // Acta dermatovenerologica Croatica, 15 (2007), 1; 50-50 (međunarodna recenzija, članak, ostalo)
CROSBI ID: 783025 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Cyclosporine in chronic idiopathic urticaria
Autori
Lipozenčić, Jasna ; Ljubojević, Suzana
Izvornik
Acta dermatovenerologica Croatica (1330-027X) 15
(2007), 1;
50-50
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo
Ključne riječi
chronic idiopathic urticaria ; treatment
Sažetak
The treatment of chronic idiopathic urticaria (CIU) is very difficult. According Vena GA et al., cyclosporine (CsA) at a dosage of 5 mg/kg per day progressively reduced to 3 mg/kg per day in addition to background therapy with cetirizine during 8 weeks may be useful in the management of CIU. This multicenter study included 99 population recruited subjects in 18 Italian outpatient clinics, all of them adult patients suffering from several relapsing CIU episodes. Exclusion criteria were other concomitant forms of urticaria, any contraindication to cetirizine and CsA (Sandimum Neoral) and relevant systemic disorders. A a 1- week run-in period with cetirizine, 10 mg/day, the patients entered a 16-week double-blind period of randomized treatment in addition to the background cetirizine therapy and were randomly allocated to one of three treatments: CsA for 16 weeks ; CsA for 8 weeks followed by placebo for 8 weeks (8-week CsA), or placebo for 16 weeks. Sixty (60%) patients reported adverse events with fever in the placebo group (elevated serum creatinine increased in six patients receiving CsA). The Subject’s Global Assessment of relief of symptoms and Dermatology Life Quality Index (DLQI) over 24-week post-randomization period proved the efficacy and point change in total score at 16 and 24 weeks. After 8 weeks, the severity score was significantly improved by CsA with relief of symptoms nd improvement in DLQI scores with CsA compared with placebo (1). This study confirmed the clinical outcome in CIU with CsA as efficient therapy at 8 weeks, as also reported by Grattan et al. (2), Cassano et al. (3), Poon et al. (4), Thompson et al. (5), and Lennox and Leahy (6).
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE